Radiopharmaceuticals are emerging as a powerful precision medicine approach in oncology, with Novartis leading the market through FDA-approved therapies Lutathera and Pluvicto generating over $2.1 billion in 2024.
Eli Lilly's 177Lu-PNT2002 demonstrated efficacy in chemotherapy-naïve mCRPC patients progressing on ARPIs, with a median rPFS of 9.5 months, compared to 6 months for ARPIs.
The SPLASH trial showed that 177Lu-PNT2002 significantly improved radiographic progression-free survival by 29% compared to standard androgen receptor pathway inhibitors in mCRPC patients.